Mesalamine-induced pneumonitis and serum sickness-like reaction

Gastroenterology and Hepatology

Volumn 3, Issue 11, 2007, Pages 875-877

  Harris, Adam ^a,b,d   Eswaran, Shanti ^a,b   Bosworth, Brian ^a,c   Gambarin Gelwan, Maya ^a,c   Scherl, Ellen J ^a,c  

^a NEW YORK PRESBYTERIAN HOSPITAL   (United States)

^b Department of Medicine   (United States)

^c WEILL CORNELL MEDICAL CENTER   (United States)

^d WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COLESTIPOL; MESALAZINE; METHYLPREDNISOLONE; STEROID;

ABDOMINAL CRAMP; ABDOMINAL PAIN; ADULT; ANEMIA; ARTHRALGIA; ARTICLE; ASCENDING COLON; BLOODY DIARRHEA; CASE REPORT; COLITIS; COLON BIOPSY; COLONOSCOPY; COMPUTER ASSISTED TOMOGRAPHY; CONSTIPATION; COUGHING; CROHN DISEASE; DEFECATION HABIT; DELAYED RELEASE FORMULATION; DRUG WITHDRAWAL; DYSPNEA; EMERGENCY WARD; ESOPHAGOGASTRODUODENOSCOPY; FECES ANALYSIS; FEMALE; FEVER; GASTRITIS; HIATUS HERNIA; HUMAN; ILEITIS; ILEUM; INTESTINE BIOPSY; IRRITABLE COLON; MYALGIA; PHYSICAL EXAMINATION; PLEURA EFFUSION; PNEUMONIA; RECTUM BIOPSY; SERUM SICKNESS; SUSTAINED DRUG RELEASE; THORAX PAIN;

EID: 37349084529     PISSN: 15547914     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Podolsky D. Inflammatory bowel disease. N Engl J Med. 2002;347:417-429.
2. Salomon P, Kornbluth AA, Aisenberg J, Janowitz HD. How effective are current drugs for Crohn's disease? A meta-analysis. J Clin Gastroenterol. 1992;14:211-215.
3. Kornbluth AA, Salomon P, Sacks HS, Mitty R, Janowitz HD. Meta-analysis of the effectiveness of current drug therapy of ulcerative colitis. J Clin Gastroenterol. 1993;16:215-218.
4. Ransford R, Langman M. Sulfasalazine and mesalamine: serious adverse reactions re-evaluated on the basis of suspected adverse reaction reports to the Committee on Safety of Medicines. Gut. 2002;51:536-539.
5. Scherl E, Bosworth B, Weine D. Crohn's and colitis at the crossroads - update 2006 part 1. Impact of new strategies on old therapies - focus on 5-ASA responders. Gastroenterol Endosc News Special Edition. 2006;4:25-29.
6. Lichtenstein G, Kamm M, Boddu P, Gubergrits N, Lyne A, et al. Effect of once- or twice- daily MMX mesalamine for the induction of remission of mild to moderately active ulcerative colitis. Clin Gastroenterol Hepatol. 2007;5:95-102.
7. Kamm MA, Sandborn WJ, Gassull M, Schreiber S, Jackowski L, et al. Once-daily, high-concentration MMX mesalamine in active ulcerative colitis. Gastroenterology. 2007;132:66-75.
8. World MJ. Mesalamine induced interstitial nephritis. Nephrol Dial Transplant. 1996;4:614-621.
9. Adachi E, Okazaki K, Matsushima Y, Seno H, Uchida K, et al. Acute pancreatitis secondary to 5-ASA therapy in a patient with ulcerative colitis. Int J Pancreatol. 1999;25:217-221.
10. Gujral N, Friedenberg F, Friedenberg J, Gabriel G, Kotler M, Levine G. Pleuropericarditis related to the use of mesalamine. Dig Dis Sci. 1996;41:624-626.
11. Waanders H, Thompson J. Kawasaki-like syndrome after treatment with mesalamine. Am J Gastroenterol. 1991;86:219-221.
12. Reinoso MA, Schroeder KW, Pisani RJ. Lund disease associated with orally administered mesalamine for ulcerative colitis. Chest. 1992;101:1469-1471.
13. Welte T, Hamm H, Fabel H. Mesalamine alveolitis. Lancet. 1991;338:1273.
14. Honeybourne D. Mesalamine toxicity. BMJ. 1994;308:533-534.
15. Danese S, Semeraro S, Papa A, Roberto I, Scaldaferri F, et al. Extraintestinal manifestations in inflammatory bowel disease. World J Gastroenterol. 2005;11: 7227-7236.
16. Herrlinger, Noftz MK, Dalhoff K, Ludwig D, Stange EF, Fellermann K. Alterations in pulmonary function in inflammatory bowel disease are frequent and persist during remission. Am J Gastroenterol. 2002;97:377-381.
17. Brimblecombe R. Mesalazine: a global safety evaluation. Scand J Gastroenterol Suppl. 1990;172:66.
18. Foster R, Zander D, Mergo P, Valentine J. Mesalamine-related lung disease: clinical, radiographic, and pathologic manifestations. Inflamm Bowel Dis. 2003;308-315.
19. Haralambou G, Teirstein A, Gil J, Present D. Bronchiolitis obliterans in a patient with ulcerative colitis receiving mesalamine. Mt Sinai J Med. 2001;68: 384-388.
20. Bitton A, Peppercorn M, Hanrahan J, Upton M. Mesalamine-induced lung toxicity. Am J Gastroenterol. 1996;91:1039-1040.
21. Muzzi A, Ciani F, Bianchini D, Festini G, Volpe C. Adverse pulmonary effects of mesalamine. Chest. 1995;108:1181.
22. Varela S, Díez MS, Gonzalez C, Gonzalez de la Cuesta C, Arenas L, et al. Oral desensitization to 5-ASA. Allergy. 2002;57:371-372.
23. Gonzalo MA, Alcalde MM, Garcia JM, Alvarado MI, Fernandez L. Desensitization after fever induced by mesalamine. Allergy. 1999;54:1224-1225.
24. Sossai P, Cappellato M, Stefani S. Can a drug-induced pulmonary hypersensitivity reaction be dose-dependent? Mt Sinai J Med. 2001;68:389-395.